Angeles Secord

Overview:

My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.

In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.

Positions:

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1994

University of Washington

Resident, Obstetrics & Gynecology

Duke University

Gynecologic Oncology Fellowship, Obstetrics & Gynecology

Duke University School of Medicine

Grants:

NCI National Clinical Trials Network U10 (Year 5)

Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Co-Principal Investigator
Start Date
End Date

Women with BRCA-mutated Advanced Stage Ovarian Cancer

Administered By
Duke Clinical Research Institute
Awarded By
AstraZeneca LP
Role
Co Investigator
Start Date
End Date

Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
Gynecologic Oncology Group
Role
Investigator
Start Date
End Date

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
American Association of Obstetricians and Gynecologists Foundation
Role
Principal Investigator
Start Date
End Date

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Publications:

Identifying disparities in gynecologic cancer: Results and analysis from a patient preference survey.

Authors
Chapman-Davis, E; Halla, KJ; Westin, SN; Salani, R; Constanzo, JD; Quill, TA; Burn, K; Secord, AA
MLA Citation
Chapman-Davis, Eloise, et al. “Identifying disparities in gynecologic cancer: Results and analysis from a patient preference survey.” Journal of Clinical Oncology, vol. 40, no. 16, 2022.
URI
https://scholars.duke.edu/individual/pub1555448
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date

Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).

Authors
Patel, MR; Makker, V; Oaknin, A; Pignata, S; Jenniskens Backes, F; Gonzalez Martin, A; Nassef Eskander, R; Pothuri, B; Richardson, DL; Alvarez Secord, A; Van Nieuwenhuysen, E; Liu, JF; Musa, F; Penson, RT; Wride, K; Lepley, DM; Dusek, R; Cameron, T; Hamilton, EP; Concin, N
MLA Citation
URI
https://scholars.duke.edu/individual/pub1555449
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date

Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Authors
Penson, RT; Arend, RC; Secord, AA; Herraez, AC; Herzog, TJ; Ledermann, JA; Moore, KN; Shapira-Frommer, R; Tewari, KS; Minei, TR; Harats, D; Shmueli, SF; Monk, BJ
MLA Citation
URI
https://scholars.duke.edu/individual/pub1555450
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date

Surgical window-of-opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia

Authors
Xu, Y; Saiz, A; Rimel, B; Corr, B; Secord, AA; Clark, LH; Kocherginsky, M; Schering, T; Benante, KA; Kalinichenko, K; Sauter, E; Samimi, G; Dimond, E; Khan, SA; Barber, EL
MLA Citation
URI
https://scholars.duke.edu/individual/pub1555451
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, globa

Authors
Secord, AA; Barroilhet, LM; Lim, MC; Gupta, S; Oosman, S; Rao, JS; Schorge, JO; Barlin, JN; Gilbert, L; Tewari, D; Gold, M; Provencher, DM; Lee, J-Y; Bixel, KL; Yanez, E; Rob, L; O'Malley, DM
MLA Citation
URI
https://scholars.duke.edu/individual/pub1555452
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date
Professor of Obstetrics and Gynecology

Contact:

Profile

https://scholars.duke.edu/person/secor002

Email

secor002@mc.duke.edu
25172 Morris Bldg, Durham, NC 27710
Box 3079 Med Ctr, Durham, NC 27710